Mouse Noggin / NOG Protein (Fc Tag)

Catalog Number: 50688-M02H



General Information

Gene Name Synonym:

NOG

Protein Construction:

A DNA sequence encoding the mouse NOG (P97466) (Met1-Cys232) was fused with the Fc region of human IgG1 at the C-terminus.

Source: Mouse

Expression Host: HEK293 Cells

QC Testing

Purity: > 85 % as determined by SDS-PAGE

Endotoxin:

< 1.0 EU per μ g of the protein as determined by the LAL method

Predicted N terminal: Gln 28

Molecular Mass:

The recombinant mouse NOG/Fc comprises 454 amino acids and has a predicted molecular mass of 51 kDa. It migrates as approximately 60 kDa band in SDS-PAGE under reducing conditions.

Formulation:

Lyophilized from sterile PBS, pH7.4

Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA. Please contact us for any concerns or special requirements.

Usage Guide

Stability & Storage:

Samples are stable for twelve months from date of receipt at -20°C to - 80°C.

Store it under sterile conditions at -20 $^{\circ}$ C to -80 $^{\circ}$ C upon receiving. Recommend to aliquot the protein into smaller quantities for optimal storage.

Avoid repeated freeze-thaw cycles.

Reconstitution:

Detailed reconstitution instructions are sent along with the products.

Bio Activity:

1.Measured by its ability to inhibit BMP4-induced alkaline phosphatase production by MC3T3-E1 cells. The ED50 for this effect is typically 0.1- $0.6\mu g/mL.<br/$ >

2.Human intestinal cancer organoids were cultured with RSPO1(Cat#11083-HNAS), EGF(Cat#50482-MNCH), NOG(Cat#50688-M02H). (Routinely tested). Data provided by D1 Medical Technology.

3.Human colorectum organoids were cultured with RSPO1(Cat#11083-HNAS), EGF(Cat#50482-MNCH), NOG(Cat#50688-M02H). (Routinely tested). Data provided by D1 Medical Technology.

4.Human lung cancer organoids were cultured with FGF2(Cat#10014-HNAE), FGF4(Cat#16043-HNAE), FGF7(Cat#10210-H07E), EGF(Cat#50482-MNCH), FGF10(Cat#10573-HNAE), NOG(Cat#50688-M02H), RSPO1(Cat#11083-HNAS). (Routinely tested). Data provided by D1 Medical Technology.

5.Human lung organoids were cultured with FGF2(Cat#10014-HNAE), FGF4(Cat#16043-HNAE), FGF7(Cat#10210-H07E), EGF(Cat#50482-MNCH), FGF10(Cat#10573-HNAE), NOG(Cat#50688-M02H), RSPO1(Cat#11083-HNAS). (Routinely tested). Data provided by D1 Medical Technology.

6.Human cholangiocarcinomas organoids were cultured with FGF2(Cat#10014-HNAE), HGF(Cat#10463-HNAS), FGF7(Cat#10210-H07E), EGF(Cat#50482-MNCH), FGF10(Cat#10573-HNAE), NOG(Cat#50688-M02H), RSPO1(Cat#11083-HNAS). (Routinely tested). Data provided by D1 Medical Technology.

7.Human liver cancer organoids were cultured with FGF2(Cat#10014-HNAE), HGF(Cat#10463-HNAS), FGF7(Cat#10210-H07E), EGF(Cat#50482-MNCH), FGF10(Cat#10573-HNAE), TGFB1(Cat#10804-HNAC), NOG(Cat#50688-M02H), RSPO1(Cat#11083-HNAS). (Routinely tested). Data provided by D1 Medical Technology.

8.Human kidney cancer organoids were cultured with FGF2(Cat#10014-HNAE), FGF7(Cat#10210-H07E), EGF(Cat#50482-MNCH), FGF10(Cat#10573-HNAE), NOG(Cat#50688-M02H), RSPO1(Cat#11083-HNAS). (Routinely tested). Data provided by D1 Medical Technology.

9.Human kidney organoids were cultured with FGF7(Cat#10210-H07E), EGF(Cat#50482-MNCH), FGF10(Cat#10573-HNAE), NOG(Cat#50688-M02H), RSPO1(Cat#11083-HNAS), HGF(Cat#10463-HNAS), FGF4(Cat#16043-HNAE). (Routinely tested). Data provided by D1 Medical Technology.

10.Human gastric cancer organoids were cultured with EGF(Cat#50482-MNCH), FGF10(Cat#10573-HNAE), NOG(Cat#50688-M02H), RSPO1(Cat#11083-HNAS). (Routinely tested). Data provided by D1 Medical Technology.

11.Human stomach organoids organoids were cultured with EGF(Cat#50482-MNCH), FGF10(Cat#10573-HNAE), NOG(Cat#50688-M02H), RSPO1(Cat#11083-HNAS). (Routinely tested). Data provided by D1 Medical Technology.

12.Human breast cancer organoids were cultured with FGF7(Cat#10210-H07E), RSPO1(Cat#11083-HNAS), IGF1(Cat#10598-HNAE), EGF(Cat#50482-MNCH), NRG1 Beta 1(Cat#11609-H01H), NOG(Cat#50688-M02H). (Routinely tested). Data provided by D1 Medical Technology.

13.Human ovarian organoids were cultured with IGF1(Cat#10598-HNAE), NRG1 Beta 1(Cat#11609-H01H), RSPO1(Cat#11083-HNAS), EGF(Cat#50482-MNCH), NOG(Cat#50688-M02H). (Routinely tested). Data provided by D1 Medical Technology.

14.Human small intestinal organoids were cultured with IL22(Cat#13059-HNAE), FGF10(Cat#10573-HNAE), EGF(Cat#50482-MNCH), NOG(Cat#50688-M02H). (Routinely tested). Data provided by D1 Medical Technology.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Tel: +86-400-890-9989 (Global), +1-215-583-7898 (USA), +49(0)6196 9678656 (Europe) Website: http://www.sinobiological.com


Mouse Noggin / NOG Protein (Fc Tag)

Catalog Number: 50688-M02H



General Information

SDS-PAGE:



Protein Description

Noggin is a secreted protein involved at multiple stages of vertebrate embryonic development including neural induction and is known to exert its effects by inhibiting the bone morphogenetic protein (BMP)-signaling pathway. It binds several BMPs with very high (picomolar) affinities, with a marked preference for BMP2 and BMP4 over BMP7. By binding tightly to BMPs, Noggin prevents BMPs from binding their receptors. Noggin binds the bone morphogenetic proteins (BMP) such as BMP-4 and BMP-7 and inhibits BMP signaling by blocking the molecular interfaces of the binding epitopes for both types I and type II receptors. Interaction of BMP and its antagonist Noggin governs various developmental and cellular processes, including embryonic dorsal-ventral axis, induction of neural tissue, the formation of joints in the skeletal system, and neurogenesis in the adult brain. Noggin plays a key role in neural induction by inhibiting BMP4, along with other TGF- β signaling inhibitors such as chordin and follistatin. Mouse knockout experiments have demonstrated that noggin also plays a crucial role in bone development, joint formation, and neural tube fusion.

References